0.3241
5.16%
-0.0148
Aditxt Inc stock is traded at $0.3241, with a volume of 201.71K.
It is down -5.16% in the last 24 hours and down -70.51% over the past month.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.
See More
Previous Close:
$0.3389
Open:
$0.3385
24h Volume:
201.71K
Relative Volume:
0.08
Market Cap:
$2.94M
Revenue:
$749.50K
Net Income/Loss:
$-29.60M
P/E Ratio:
-0.000862
EPS:
-376.0263
Net Cash Flow:
$-22.09M
1W Performance:
-7.78%
1M Performance:
-70.51%
6M Performance:
-99.61%
1Y Performance:
-99.77%
Aditxt Inc Stock (ADTX) Company Profile
Name
Aditxt Inc
Sector
Industry
Phone
909-488-0844
Address
737 N. FIFTH STREET, SUITE 200, RICHMOND
Compare ADTX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
ADTX | 0.3241 | 2.94M | 749.50K | -29.60M | -22.09M | -376.03 |
VRTX | 447.00 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 742.11 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 588.93 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 249.68 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 103.55 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Aditxt Inc Stock (ADTX) Latest News
Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 - Marketscreener.com
Aditxt extends merger agreement end date to January 2025 By Investing.com - Investing.com UK
Appili Therapeutics Moves Forward with Aditxt Acquisition - TipRanks
Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc. - The Manila Times
Aditxt Inc. (ADTX) Quarterly 10-Q Report - Quartz
Aditxt, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
ADTX stock plunges to 52-week low of $0.32 amid market challenges - Investing.com Canada
Evofem Cuts Q3 Operating Loss 31%, Acquires SOLOSEC Rights Despite Sales Dip | ADTX Stock News - StockTitan
Enviri Corp (NYSE: NVRI): Blank Check On Growth? - Stocks Register
Appili Therapeutics shareholders vote in favor of Aditxt transaction - TipRanks
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025 - The Manila Times
Aditxt, Inc. (NASDAQ:ADTX) Short Interest Update - Defense World
Aditxt suspends equity financing amid acquisition strategy - Investing.com
Aditxt suspends equity financing amid acquisition strategy By Investing.com - Investing.com UK
ADTX stock plunges to 52-week low, touches $0.42 - Investing.com India
ADTX stock plunges to 52-week low, touches $0.42 By Investing.com - Investing.com UK
Aditxt Secures Overwhelming Shareholder Approval for Appili Therapeutics Acquisition | ADTX Stock News - StockTitan
Appili Shareholders Approve Acquisition by Aditxt - TipRanks
Appili Therapeutics Announces Results of Special Meeting of Shareholders - Financial Post
Appili Therapeutics Announces Results of Special Meeting of Shareholders - GlobeNewswire Inc.
Aditxt announces Evofem secures voting agreements with investors for merger - TipRanks
Evofem Biosciences Gains Support for Aditxt Merger - TipRanks
Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem - Quantisnow
Evofem Secures Investor Support for Proposed Merger through Voting Agreements - StreetInsider.com
Evofem Secures Key Merger Support as Aditxt Completes $5M Investment Commitment | ADTX Stock News - StockTitan
Aditxt Discloses Information About Compliance with Nasdaq Listing Requirements in 8-K Filing** - Defense World
Aditxt, Inc. Focuses on Growth Amid Nasdaq Compliance - TipRanks
A Biotech Empire Rises in Inland Southern California - Site Selection Magazine
Aditxt receives positive FDA feedback on ATI-1801 development By Investing.com - Investing.com Australia
ADTXAditxt, Inc. Latest Stock News & Market Updates - StockTitan
Aditxt receives positive FDA feedback on ATI-1801 development - Investing.com India
Evofem Biosciences enters agreements amid merger plans - Investing.com
Evofem Biosciences Faces Merger and Credit Challenges - TipRanks
Evofem Biosciences enters agreements amid merger plans By Investing.com - Investing.com UK
ADTX stock plunges to 52-week low of $0.53 amid market challenges - Investing.com
Aditxt’s Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission - StockTitan
Appili Therapeutics’ FDA Alignment and Aditxt Acquisition - TipRanks
Appili Therapeutics announces FDA alignment on ATI-1801 NDA requirements - TipRanks
Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission - The Manila Times
Aditxt Enters Major Investment Agreement with Evofem - TipRanks
Aditxt appoints Sylvia Hermina to board By Investing.com - Investing.com Canada
Sylvia Hermina Joins Aditxt's Board of Directors, Elevating Leadership with Broader Perspectives - Quantisnow
Aditxt appoints Sylvia Hermina to board - Investing.com
Aditxt, Inc. Appoints Sylvia Hermina to its Board of Directors - Marketscreener.com
Evofem Biosciences, Inc. announced that it has received $2.28 million in funding from Aditxt, Inc. - Marketscreener.com
Is Aditxt Inc (NASDAQ: ADTX) Doomed From The Get-Go? - Stocks Register
Evofem Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits - Quantisnow
Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem - Quantisnow
ADTX stock touches 52-week low at $0.89 amid sharp decline - Investing.com UK
Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier, Moderated by MD & Media Personality Dr. Drew Pinsky, on October 28, 2024, at 11:30 AM Eastern Time - StockTitan
Aditxt shares sold by major stakeholder HRT Financial for $29,874 - Investing.com South Africa
Aditxt Inc Stock (ADTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aditxt Inc Stock (ADTX) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
HRT FINANCIAL LP | 10% Owner |
Oct 16 '24 |
Sale |
1.17 |
25,534 |
29,875 |
0 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):